The Downstream Impacts of High Drug Costs for PrEP Have Hindered the Promise of HIV Prevention.

Prior to the recent introduction of generic TDF/FTC in the U.S., access to pre-exposure prophylaxis (PrEP) for HIV was greatly limited due to the downstream effects of the high cost of the medication.